Folotyn for Non-Hodgkin's Lymphoma Huntington Station NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

DAVID CHU, MD
(631) 751-3000
235 N Belle Mead Road
East Setauket, NY
Richard Matthew Lee, MD
516-536-0455
242 Merrick Rd Ste 301
Rockville Centre, NY
Steven Charles Carabell, MD
516-222-2022
990 Stewart Ave
Garden City, NY
Sean William Dowling, MD
203-966-0397
34 Shelburne Rd
Stamford, CT
Sam Maz, MD
516-562-8900
300 Community Dr
Manhasset, NY
Myron Arlen
(516) 487-9454
600 Northern Blvd
Great Neck, NY
Monique Chang, MD
516-663-9500
200 Old Country Rd Ste 450
Mineola, NY
Stefan Berger, MD
516-766-0500
2000 N Village Ave Ste 208
Rockville Centre, NY
Paul Leslie Weinstein, MD
203-325-2695
34 Shelburne Rd
Stamford, CT
Rudy Thomas Andriani, MD
203-356-9692
166 W Broad St Ste 404
Stamford, CT
Data Provided by:
    

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Huntington Station NY
For most patients with acute myeloid leukemia (AML) who come out of remission, donor stem cells appear to offer the best shot at survival, a new analysis shows.
- Green Tea and Hematologic Malignancies Huntington Station NY